ResMed Inc. (ASX:RMD) Reports Q1 2025 Financial Results
ResMed Inc. (ASX:RMD) reports Q1 2025 revenues up 8% and diluted EPS of $2.48, declaring a $0.53 dividend per share.
The Hub of Australian Finance News
ResMed Inc. (ASX:RMD) reports Q1 2025 revenues up 8% and diluted EPS of $2.48, declaring a $0.53 dividend per share.
Eagle Mountain Mining (ASX:EM2) completes rights issue, raising A$5.9 million and advancing key projects.
Surefire Resources NL (ASX:SRN) extends Yidby gold mineralisation, advances copper systems, secures offtake agreement, and receives R&D rebate.
Future Battery Minerals (ASX:FBM) announces key gold targets at Kal North and expands Western Australia landholdings, enhancing exploration prospects.
Australian Rare Earths Limited (ASX:AR3) finalises farm-in agreement for EL6678, expanding its Overland Uranium Project with promising exploration results.
PYC Therapeutics (ASX:PYC) extends cash runway to over $200m and advances polycystic kidney disease program in Q1 2025.
Hot Chili Limited (ASX:HCH) releases the Costa Fuego PFS and maiden ore reserve, highlighting robust financials and significant exploration advancements.
Cynata Therapeutics (ASX:CYP) reports progress in key clinical trials and maintains a strong financial position in Q1 2025.
Perpetual Resources (ASX:PEC) reports exceptional high-grade lithium and caesium assays at the Igrejinha Project, preparing for its maiden drill campaign in June.
Raiz Invest (ASX:RZI) announces strong Q3 FY25 growth with increased active customers, ARPU, and Funds Under Management.